Immunosuppression resulting from HIV infection increases the risk of progression to active tuberculosis (TB) both in individuals newly exposed to Mycobacterium tuberculosis (MTB) and in those with latent infections. We hypothesized that HIV-positive individuals who do not develop TB, despite living in areas where it is hyperendemic, provide a model of natural resistance. We performed a genome-wide association study of TB resistance by using 581 HIV-positive Ugandans and Tanzanians enrolled in prospective cohort studies of TB; 267 of these individuals developed active TB, and 314 did not. A common variant, rs4921437 at 5q33.3, was significantly associated with TB (odds ratio ¼ 0.37, p ¼ 2.11 3 10
Introduction
Mycobacterium tuberculosis (MTB) and HIV are major causes of infectious-disease mortality worldwide. 1, 2 In 2014, more than 25% of the 1.5 million people who died from active tuberculosis (TB) were HIV positive, and the great majority were in sub-Saharan Africa. 1, 2 The immunosuppression resulting from HIV infection increases the risk of progression of an MTB infection to active disease both in individuals newly exposed to MTB and in those with latent infections. 3, 4 Various approaches to studying the relationship between host genetics and TB, including genome-wide association studies (GWASs) in sub-Saharan Africa, have been published. [5] [6] [7] The GWAS results have not explained a substantial portion of the genetic risk, possibly owing to the cross-sectional ascertainment of control individuals, which does not guarantee MTB exposure; this will most likely reduce estimated effect sizes as a result of increased noise. These studies compared immunocompetent case and control individuals in search of common variation that affects disease risk in the general population. An alternative approach, which we have taken, is to identify cohorts at extreme risk and focus on genetic factors that prevent the development of active disease despite this increased vulnerability. All previous studies of human genetic susceptibility to TB have used HIV-seropositive status as an exclusion criterion or adjusted for it as a potential confounder in the analyses. [6] [7] [8] [9] Here, we hypothesized that HIV-positive individuals who do not develop TB, despite living in areas hyperendemic for MTB, are highly resistant. Using prospective cohorts of TB in East Africa, we compared this extreme control group to HIV-positive individuals with TB. We identified a genome-wide-significant variant in a regulatory region near IL12B (MIM: 161561), a gene involved in cellmediated immunity against intracellular bacteria.
Subjects and Methods

Study Populations
Samples were analyzed from three prospective studies, two from Tanzania and one from Uganda. All three were designed to assess different aspects of TB risk or progression but had comparable data available for most variables. All individuals who participated in our study provided written informed consent.
Tanzania
Participants were recruited from the extended follow-up cohort of the DarDar vaccine trial. This cohort has been previously described. 10 In brief, the DarDar trial was a randomized doubleblind phase 3 trial of an inactivated whole-cell mycobacterial vaccine (SRL 172). Subject enrollment occurred between 2001 and 2005, and the study was concluded in 2008. All enrolled individuals were HIV-positive adults (>18 years old) with a CD4 count > 200 cells/ml, had a Bacille Calmette-Guérin childhood vaccination scar, and were TB negative at the time of enrollment.
The final study population consisted of 1,007 individuals in the placebo arm and 1,006 in the vaccine group. Participants were routinely followed up every 3 months and evaluated for active TB through a physical examination, a chest radiograph, sputum samples for culture and acid-fast bacilli (AFB) stain, and phlebotomy for an automated mycobacterial blood culture. At the conclusion of the study, a cohort of 800 total participants in both the placebo and vaccine arms were selected for extended follow-up. These individuals have been evaluated for active TB once a year since the conclusion of the study. We recruited 304 of the extended-followup participants between September and December 2013 during their routine visits. 36 of the individuals had been diagnosed with definite or probable TB since the onset of the trial. Diagnostic criteria are described in von Reyn et al. 10 Individuals who did not develop TB during follow-up but stated that they had previous active TB were excluded from the study because those diagnoses could not be confirmed (exclusion criteria and the remaining sample size are provided in Table S1A ). As with most genetic association studies of TB, it was not possible to determine with certainty whether our control subjects were exposed to MTB during the course of the study. However, such exposure in Dar es Salaam is highly likely. This conclusion is based on the length of followup (at least 8 years) and the high prevalence of TB in Tanzania, which is among the highest in the world at 528 per 100,000 individuals. 11 Additionally, this prevalence estimate is based on a country average, and it has been shown that such national-surveillance values underestimate urban incidence. 12 We also used previously collected samples from the DarDar nutrition study in Dar es Salaam, Tanzania. 13 The DarDar nutrition study was a randomized, controlled trial assessing the effectiveness of a protein-calorie supplement (PCS) on standard TB and HIV treatment in women. All enrolled women were HIV-positive adults (>18 years old) and had newly diagnosed active TB. 150 participants were randomized to either a PCS arm or a multivitamin control group. Treatment protocols recommended by the World Health Organization were followed through the Tanzanian Ministry of Health National Tuberculosis and Leprosy Program. Subjects were followed monthly until the completion of the study in 2014. Available samples from 85 participants of the DarDar nutrition study were used. Uganda We used samples from participants of the household-contact (HHC) study conducted in Kampala, Uganda, from 2002 to 2014. This cohort has been previously described. 14, 15 In brief, the HHC combined case-control and family-based designs to analyze the genetic epidemiology of TB. Individuals diagnosed with new active TB were referred to the study through the Uganda National Tuberculosis and Leprosy Programme, and those who consented were enrolled as index subjects. Relatives and unrelated individuals living within the same household were subsequently enrolled and evaluated for active TB, latent TB, and HIV. Both index and incident subjects of active TB were given the recommended therapy. 16 Importantly, selecting our TB case and control individuals from the incident contacts guaranteed exposure of the control individuals because of their proximity to the index individuals. 14 
DNA Isolation and Genotyping
For participants from the DarDar vaccine trial, 5 ml of whole blood was drawn into EDTA-coated tubes (BD Biosciences) and immediately stored at 4 C. DNA was extracted the day of the phlebotomy with the Gentra Puregene Blood Kit (QIAGEN) in accordance with the manufacturer's recommendations in Dar es Salaam. For participants of the DarDar nutrition and HHC studies, buffy coats were isolated on site and shipped to Dartmouth College for DNA extraction. DNA was isolated from buffy coats with the QIAamp DNA Blood Mini Kit (QIAGEN). All DNA samples were stored at À80 C prior to genotyping.
All available samples from the DarDar vaccine trial (n ¼ 304), the DarDar nutrition study (n ¼ 85), and the HHC study (n ¼ 263) were selected for genotyping. DNA quality was evaluated according to the 260/280 ratio with a NanoDrop 2000 spectrophotometer (Thermo Scientific) and an electrophoresis quality score. After quality control, a total of 639 samples were genotyped with the Human Core Exome BeadChip (542,585 SNPs) at the Hussman Institute for Human Genetics in Miami. After applying the exclusion criteria of adult age (R18 years old) and no history of prior active TB, we analyzed the remaining participants, who consisted of 283 participants from the DarDar vaccine trial, 75 participants from the DarDar nutrition study, and 234 participants from the HHC study (Table S1A) . SNPs with a genotyping call rate > 0.95 and a HardyWeinberg equilibrium p value > 1.00 3 10 À4 were retained. All remaining participants had a per-individual genotyping call rate > 0.95. A sex check was performed, and cryptic relatedness was evaluated in PLINK (v.1.07). 18 From each pair of related study participants, one individual was randomly removed (pi-hat > 0.20).
The final study population genotyped on the Exome BeadChip included 278 participants from the extended follow-up of the DarDar vaccine trial, 65 participants from the DarDar nutrition study, and 213 participants from the HHC study. Samples from 64 additional HIV-positive Ugandan HHC participants were genotyped with an Illumina HumanOmni5-Quad BeadChip (4.8 million SNPs). DNA was extracted from buffy coats with the QIAamp DNA Mini Kit (QIAGEN) and quantified with NanoDrop and Qubit. Genotyping and DNA quality checking were done at the Genomics Core at Case Western Reserve University. Further quality-control steps for samples included checking for sexmismatch errors, relationship errors (within the larger dataset of 483 samples), consistency of blind duplicates, call rate (>95%), tenth percentile GenCall score (>0.42), visual inspection of the B-allelefrequency plot of samples with a <98% call rate, and unusually high autosomal heterozygosity. Individuals < 18 years old and those related to the participants genotyped with the Exome BeadChip (pihat > 0.20) were excluded. 25 of the additional 64 individuals remained after we applied these exclusion criteria.
For the samples used in the selection analyses, after phlebotomy, white blood cells were isolated by a modified salting-out procedure, 19 and DNA was extracted with a Puregene DNA Extraction Kit (Gentra Systems). 17 The samples were genotyped with the Illumina Human 1M-Duo BeadChip. 17 We evaluated cryptic relatedness by randomly removing individuals with pi-hat > 0.25, and we removed SNPs with call rates less than 95%. All quality-control measures were done in PLINK (v.1.07). 18 Admixture was evaluated by principal-component analysis in R 20 and STRUCTURE as previously described. 17 
Immunological Data
Enrollment CD4 counts were available for 437 subjects, including all participants of the extended follow-up of the DarDar vaccine trial and nutrition study and HHC study participants who enrolled after 2004. CD4 counts were not ascertained for individuals who entered the HHC study before 2004 (n ¼ 144) because antiretroviral therapy was unavailable in Uganda before then. All participants of the DarDar nutrition study were affected by TB, and the design of the HHC study guaranteed exposure to MTB. To address possible confounding of our results by exposure in the extended follow-up of the DarDar vaccine trial, we leveraged available interferon-g (IFN-g) release assay (IGRA) data. Immune response to Mycobacteria was assessed with an IFN-g ELISA, a tritiated thymidine lymphocyte proliferation assay (LPA), and ELISA for antibodies to the MTB glycolipid lipoarabinomannan (LAM). The assays used in this study have been previously described. 21 In brief, IFN-g and LPA assays used four different antigens in the samples from Tanzania: Mycobacterium vaccae sonicate (2 mcg/ml), MTB antigen 85 (Ag85; 1 mcg/ml), MTB early secretory antigenic target 6 (ESAT-6; 2 mcg/ml), and MTB whole-cell lysate (1 mcg/ml). 21 Media alone served as a negative control, and phytohemagglutinin (2.5 mcg/ml; Sigma) was used as a positive control. 21 
Statistical Analyses
Logistic regression in PLINK (v.1.07) 18 was used for testing the association between single SNPs in an additive model and active TB case-control status. A priori power analyses in QUANTO revealed that a minor allele frequency (MAF) > 0.20 should be used in both cohorts in the single-SNP association analyses. 22 Summary statistics for available covariates were calculated in STATA (v.11.2). 23 Covariate data were analyzed for differences between Table S1B ); therefore, it was not adjusted for. Because the Tanzanian cohorts were recruited in Dar es Salaam and the Ugandan cohort was recruited in Kampala, both large urban centers, admixture was a likely confounder in this study. To adjust for population structure within each country, we used the SNPRelate package in R 20, 24 to calculate principal components separately for participants from Uganda and Tanzania by using SNPs with r 2 < 0.1, a MAF > 0.2, and a genotype call rate > 0.95. Analyses of the combined cohorts were also adjusted for country of origin. Data on self-reported tribal identity were available for the individuals from Uganda. The first, sixth, and seventh principal components were significant in predicting membership from the predominant tribe, Muganda (63% of the participants), versus all others. Because self-described ethnicity was not available for Tanzania, we conservatively chose to use ten principal components (Table S2) . We used locus zoom to plot the region of the SNP with the strongest association 25 ( Figure 1 ). SNPs in the region of interest (rs4921437 position 5 1 Mb) were imputed with IMPUTE2 (v.2.3.1) and one multi-population phased reference panel from the 1000 Genomes Project.
26-28
We performed logistic-regression analysis of TB in the combined cohort while adjusting for CD4 count at enrollment, sex, country of origin, and ten principal components in 437 individuals for whom CD4 data were available (Table S3A) . To assess the effect of variable immunosuppression of case and control individuals on the association results, we repeated this analysis without adjustment for CD4 counts in the same subset of individuals (Table S3B ). We performed logistic-regression analyses of TB with IGRA results in the extended follow-up of the DarDar vaccine trial (Table S4) .
We examined all pairwise haplotypes within the locus of interest, i.e., the region that included our most significant SNP, rs4921437. The additional SNPs were selected on the basis of MAF > 0.05. 11 unimputed SNPs passed quality control and spanned IL12B and UBLCP1 (MIM: 609867), and we used these to test for haplotype association (Figures S1A and 1B) . This region was defined with Haploview. 29 We performed haplotype association analyses with UNPHASED (v.3.1.7) 30 while adjusting for the same covariates as in the single-SNP association analyses. We then performed a single three-SNP haplotype analysis with SNPs from the two most significant pairwise haplotypes (Table S5) 
Functional Annotation
The ENCODE Project 39 was accessed via the UCSC Genome Browser, 37 and data provided by the Bernstein lab were used for functional annotation.
Results
The combined study population consisted of 267 individuals with TB (100 from Tanzania and 167 from Uganda) and 314 control individuals (243 from Tanzania and 71 from Uganda; Table S1 ). Male gender associated with active Using logistic regression, we observed a genome-wide-significant association between common variant rs4921437 and TB (OR ¼ 0.37, 95% CI ¼ 0.27-0.53, p ¼ 2.11 3 10 À8 ; Table 1 and Figure S2A Table 1 and Figures S2B and S2C) . The genomic inflation factor (l) for the final adjusted logistic-regression model was 1.029 for analysis of the cohorts combined, 1.023 for analysis of samples from Tanzania, and 1.056 for analysis of samples from Uganda. The cluster plot for rs4921437 shows that genotype calling for this SNP was unambiguous for virtually all samples ( Figure S3 ). These results indicate not only that the combined association is highly significant but also that each cohort alone provides strong evidence of association; rs4921437 was the most significant SNP in 
RBFOX1
Results are presented for the Ugandan cohort, the Tanzanian cohorts, and the combined cohorts. All analyses were adjusted for principal components and sex; the combined analyses were also adjusted for country of origin. Abbreviations are as follows: Chr, chromosome; CI, confidence interval; MAF, minor allele frequency; and OR, odds ratio. Other SNPs between rs557438 and rs4921437 are statistically significant but are not relevant here. b Closest protein-coding gene.
Uganda and was among the most significant in Tanzania (Figures S2A-S2C) . We imputed all SNPs within 1 Mb of rs4921437. Imputed variant rs10515780, only 842 bp from rs4921437, displayed the most significant association with TB (combined cohort OR ¼ 0.34, 95% CI ¼ 0.24-0.49, p ¼ 6.21 3 10 À9 ; Figure 1 and Table S6 ). This SNP was in very high linkage disequilibrium (LD) with the index SNP (D 0 ¼ 1 in both cohorts, r 2 ¼ 0.84 in Tanzania and 0.89 in Uganda) and was imputed with a high degree of certainty (imputation certainty was 0.993 in both Tanzania and Uganda). Variants rs4921437 and rs10515780 map to an intron in UBLCP1, ubiquitin-like-domain-containing C-terminal domain phosphatase 1. Variant rs4921437 is 51 kb away from the 3 0 UTR of IL12B. According to ENCODE, 39 both rs4921437 and rs10515780 are located in an H3K27Ac histone mark that most likely represents a regulatory region (Figure 1) . Adjustment for CD4 counts in the subset of participants for whom we had data (n ¼ 437) demonstrated that variable immunosuppression among case and control individuals was not a confounding factor (Table S3 ). Prior MTB exposure of the control group is essential, and our cohorts virtually assured it. All individuals from the DarDar nutrition study were affected by TB. The HHC study design guarantees exposure of the TB-negative individuals to MTB, given that co-habitation with an individual with active TB was a prerequisite for enrollment. Although direct contact with index individuals with active TB was not assessed in the DarDar vaccine trial, 8 years had elapsed between the completion of enrollment for the vaccine trial and recruitment into our study, and TB prevalence in Tanzania is among the highest in the world (see Subjects and Methods). Therefore, participants were both HIV positive and living in an area hyper-endemic for TB at least this long, virtually guaranteeing MTB exposure. Nevertheless, to address possible confounding by lack of exposure, we assessed response of IGRAs and LPAs by case-control status and observed no statistically significant differences (Table  S4) . Although the Ugandan and Tanzanian studies were designed differently, the consistency in genetic association results underscores the robustness of this finding.
Analysis of the UBLCP1-IL12B region in the unimputed dataset revealed blocks of LD between rs4921437 and SNPs in IL12B in the Ugandan and Tanzanian cohorts, as well as in African samples from phase 3 of the HapMap Project ( Figure S1 ). A three-variant haplotype of rs4921437, rs4921468 (intergenic), and rs3213094 (intronic in IL12B) had a more significant association with TB than rs4921437 alone in the combined cohort (p ¼ 4.56 3 10 À15 ) (Table S5) . Results were consistent when the Ugandan and Tanzanian cohorts were analyzed separately (p ¼ 1.98 3 10 À11 and 4.56 3 10
À5
, respectively). When we conditioned an rs4921468-rs3213094 haplotype analysis on the main-effect variant, rs4921437, the combined cohort haplotype association was significant at a multipletesting-corrected threshold based on the number of SNPs re-
À7
). Frequencies of the three-variant haplotype were not significantly different between the Ugandan and Tanzanian cohorts, nor among founders of the LWK or ASW (African ancestry in Southwest USA) from phase 3 of HapMap (Table S7) . 32 This conservation of haplotype frequencies among these Africa-derived samples was unexpected given the known diverse history of these populations and genomic differentiation between them. 40 Frequencies of the three-variant haplotype in Uganda and Tanzania were significantly different from those in all other HapMap phase 3 populations (Table S7) . 32 We assessed whether allele-frequency distributions were consistent with selection. The ancestral, minor allele of rs4912437 (T), which associated with TB resistance, had a MAF of 0.21 in our combined cohort (0.21 in both Tanzania and Uganda). In the African, European, and South Asian origin populations from phase 3 of the HapMap Project and the 1000 Genomes Project, the T allele frequency varied between 0.11 and 0.36 (Table  S8) . 32 The MAFs in the Biaka Pygmy and Mbuti Pygmy populations of the Human Genome Diversity Project were 0.45 and 0.46, respectively. Of note, the ancestral variant had a very low frequency in East Asian populations for which data are available (MAF < 0.025), suggesting either a loss due to drift or its maintenance due to selection where the allele remained. We found highly similar LD patterns over the entire IL12B region in our Tanzanian and Ugandan cohorts ( Figure S1 ). Considering previously documented patterns of less LD and greater variation of LD among African populations, 41 we did not expect to find such striking similarities. We then evaluated signatures of selection by using an iHS 38 in equatorial African populations (West Pygmy, Datog, and Niger-Kordofanian-West) for which we had available data with coverage adequate for these analyses. 42 The iHS test is most sensitive to recent adaptive events (<25,000 years ago), appropriate here because TBrelated selective pressure is thought to have increased after agriculture-associated growth in population density. 38, 42 Two intronic SNPs in IL12B (4,672 bp apart) were in the top 0.1% of the distribution of absolute values of iHSs for one million genotyped SNPs in at least one equatorial African population ( Table 2 ). The region surrounding rs3213093 had a signature of selection in the top 0.1% of the distribution in the Datog population sample, whereas the region centered on rs2421047 had a signature of selection in the top 0.1% of the distribution in the Niger-Kordofanian-West population samples (Table 2 ). In our study cohorts, rs3213093 and rs2421047 were in high LD with each other ( À4 . This SNP is 715 bp away from rs1840680, a previously associated variant in a West African population, 43 and it is in strong LD with it in the LWK 1000 Genomes population (r 2 ¼ 0.86). We imputed rs1840680, and it associated with a p value of 0.0013 and an OR of 1.63 (Table 3 ). Variants rs2057178, rs4331426, and rs4733781, which previously associated with TB in genome-wide analyses, had ORs similar to those previously reported (rs2057178: OR ¼ 0.84 in our combined cohort versus 0.77 in Thye et al. 6 ; rs4331426:
OR ¼ 1.16 in our combined cohort versus 1.18 in Thye et al. 7 ; and rs4733781: OR ¼ 0.92 in our combined cohort versus 0.84 in Curtis et al. 5 ). However, our sample size was smaller than those in the reported studies, and the SNPs were not significant in our analyses (Table 3) . These results, even though not significant, support the validity of our cohort design and phenotype definitions.
Discussion
Our approach to the study of TB genetics focuses on resistance as opposed to susceptibility. Specifically, we hypothesized that HIV-immunocompromised individuals who resist TB despite prolonged exposure represent an extreme phenotype that can provide new insights into TB pathogenesis. We identified a region encompassing IL12B, a gene originally shown to underpin a very rare monogenic immunodeficiency that promotes high susceptibility to several mycobacterial infections. 44 Unlike Mendelian immunodeficiency-causing mutations identified in subjects presenting with hyper-susceptibility to infection, resistance variants only emerge as conferring noticeable protection in high-risk yet disease-free subjects. Our HIV-positive cohorts enabled us to find a variant that has a much larger effect size than previously associated common SNPs, one detected with a sample size well below that of most published GWASs. Also, in contrast to most previous TB association studies that have used cross-sectional selection of the control group, in our study the control individuals were ascertained as part of long-term, well-characterized, prospective cohorts. This is a distinct strength of our design; individuals were routinely tested for TB. Furthermore, in the subset of individuals for whom CD4-count data and IGRA data were available, we did not observe any confounding by extent of immunosuppression or exposure to MTB.
Our SNP of primary interest is located in an area enriched with a histone acetylation mark often found in active regulatory elements, suggesting functionality. The H3K27Ac annotation indicates a modification that acts in concert with an H3K4Me1 mark to differentiate active enhancer elements from poised or inactive ones. 45, 46 Such chromatin modifications are associated with higher regulatory responses at enhancer transcription factor binding sites, 45 possibly potentiating the effect of DNA polymorphisms in the region. The variants with the strongest association with TB are located in introns of UBLCP1, previously shown to regulate nuclear proteasome activity. 47 Variants in this gene have been previously associated with carotid stenosis, 48 psoriasis, 49 and platelet aggregation. 50 Importantly, these SNPs are also in proximity to IL12B, a gene previously associated with both TB IL-23 also plays a role in controlling MTB infection; it is essential for the differentiation of naive T cells into Th17 cells, which are responsible for the production of IL-17.
63
IL-17 is necessary for the targeting of neutrophils to the site of infection, and IL-17-deficient mice are unable to control highly virulent MTB strains. 63, 64 Therefore, although our analyses do not provide direct evidence of association with IL12B, it remains a gene of substantial interest on the basis of both our results and prior data relating this locus to TB and related phenotypes. Additional evidence supporting the detected association derives from the high concordance of LD patterns across several African-descent populations in the IL12B region. Analyses using other sub-Saharan populations demonstrated that the IL12B region has undergone positive selection. These results demonstrate strong selection in the region of interest in populations related to our study cohorts, although the selection signature appears to be strongest within IL12B and not in the regulatory region in which rs4921437 is located. This lower value might be due to the SNP location, near the end of the UBLCP1-IL12B haplotype block. 38 Because the IL12B locus has pleiotropic effects, we cannot rule out that other historical intra-cellular pathogens, such as Plasmodium falciparum or Yersinia pestis, 65 have exerted selective pressure on this gene. The high prevalence of HIV-MTB co-infection in subSaharan Africa, along with persisting rates of multi-drugresistant TB, necessitates development of new treatment modalities tailored to this population. 2 Previous studies of exogenous IL-12 administration in murine models have shown efficacy in limiting disease progression.
Cooper et al. demonstrated that survival of MTB-infected mice with severe combined immunodeficiency was extended with IL-12 treatment. 66 Nolt et al. reported improved survival, diminished bacterial loads, and decreased pulmonary inflammation in CD4-deficient mice 8 weeks after IL-12 therapy. 67 Reduced granuloma formation and decreased inflammation were also observed in the lungs of wild-type mice. 67 The strong association between TB and a common variant near the gene encoding an IL-12 subunit in an HIV-positive host population links the murine observations to the human phenotype. IL-12 and members of its pathway are therefore promising candidates for development of new TB treatments, which could be efficacious in both HIV-positive individuals and the general population.
In conclusion, we have identified a locus conferring strong resistance to TB, thereby demonstrating that use of extreme phenotypes can be a powerful strategy for unraveling the host genetics of complex infectious diseases. This approach reduces the noise caused by both phenotypic and genetic heterogeneity, allowing detection of signals from major genes even in seemingly underpowered studies.
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